Compare Grab Holdings Ltd. (GRAB) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Twist Bioscience Corp — how do they compare? Grab Holdings Ltd. trades at $3.72 (market cap $15.62B), while Twist Bioscience Corp trades at $93.31 (market cap $5.76B). The key difference: Grab Holdings Ltd. is far larger — about 2.7× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | TWST | |
|---|---|---|
Market Cap | $15.62B | $5.76B |
Sector | Technology | Health |
52-Week High | $6.45 | $102.88 |
52-Week Low | $3.27 | $24.16 |
Enterprise Value | $11.32B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.80, down 3.55% today but showing strong fundamental improvement with revenue growth from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Technical indicators show a bullish overall signal with neutral oscillators. Recent news highlights CEO share sales and Uber CEO's board departure, creating mixed sentiment despite analyst optimism.
The outlook remains positive with 91.67% analyst buy ratings and a $5.45 consensus target offering 43% upside. Key risks include competitive pressures in Southeast Asia's ride-hailing market and volatile cash flow patterns, but sustained revenue growth and margin expansion support long-term potential.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
